208 related articles for article (PubMed ID: 35131410)
1. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.
Mullur J; Steger CM; Gakpo D; Bensko JC; Maurer R; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 May; 128(5):575-582. PubMed ID: 35131410
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.
Sweis AM; Locke TB; Ig-Izevbekhai KI; Lin TC; Kumar A; Douglas JE; Corr AM; Civantos AM; Tripathi SH; Kennedy DW; Kohanski MA; Palmer JN; Adappa ND; Bosso JV
Allergy Asthma Proc; 2021 Mar; 42(2):136-141. PubMed ID: 33685558
[No Abstract] [Full Text] [Related]
3. Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Mullur J; Buchheit KM
Ann Allergy Asthma Immunol; 2023 Sep; 131(3):317-324. PubMed ID: 37225000
[TBL] [Abstract][Full Text] [Related]
4. Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?
Laidlaw TM; White AA
J Allergy Clin Immunol Pract; 2024 Jan; 12(1):79-84. PubMed ID: 37778627
[TBL] [Abstract][Full Text] [Related]
5. Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Laidlaw TM; Chu DK; Stevens WW; White AA
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1462-1467. PubMed ID: 34999274
[TBL] [Abstract][Full Text] [Related]
6. Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease.
Sweis AM; Locke TB; Ig-Izevbekhai KI; Lin TC; Gleeson PK; Civantos AM; Kumar A; Corr AM; Kohanski MA; Palmer JN; Bosso JV; Adappa ND
Int Forum Allergy Rhinol; 2021 Feb; 11(2):115-119. PubMed ID: 32671928
[TBL] [Abstract][Full Text] [Related]
7. [Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : Results of a multicentric study].
Staufenberg AR; Frankenberger HK; Förster-Ruhrmann U; Spahn FC; Klimek L; Fruth K; Stihl C; Matthias C; Gröger M; Hagemann J
HNO; 2024 Jul; 72(7):473-483. PubMed ID: 38466409
[TBL] [Abstract][Full Text] [Related]
8. Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease.
Jean T; Eng V; Sheikh J; Kaplan MS; Goldberg B; Jau Yang S; Samant S
Allergy Asthma Proc; 2019 Sep; 40(5):316-320. PubMed ID: 31514790
[No Abstract] [Full Text] [Related]
9. Omalizumab can inhibit respiratory reaction during aspirin desensitization.
Lang DM; Aronica MA; Maierson ES; Wang XF; Vasas DC; Hazen SL
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):98-104. PubMed ID: 29777744
[TBL] [Abstract][Full Text] [Related]
10. The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD).
Spies JW; Valera FC; Cordeiro DL; de Mendonça TN; Leite MG; Tamashiro E; Arruda LK; Anselmo-Lima WT
Braz J Otorhinolaryngol; 2016; 82(3):263-8. PubMed ID: 26601997
[TBL] [Abstract][Full Text] [Related]
11. The chronic rhinosinusitis practice parameter.
Kim SL; Rank MA; Peters AT
Ann Allergy Asthma Immunol; 2023 Sep; 131(3):307-310. PubMed ID: 37667905
[TBL] [Abstract][Full Text] [Related]
12. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Wangberg H; Spierling Bagsic SR; Osuna L; White AA
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):478-484.e3. PubMed ID: 34597850
[TBL] [Abstract][Full Text] [Related]
13. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.
Stevens WW; Jerschow E; Baptist AP; Borish L; Bosso JV; Buchheit KM; Cahill KN; Campo P; Cho SH; Keswani A; Levy JM; Nanda A; Laidlaw TM; White AA
J Allergy Clin Immunol; 2021 Mar; 147(3):827-844. PubMed ID: 33307116
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease Based on the 12-Item Short Form Survey.
Locke TB; Sweis AM; Douglas JE; Ig-Izevbekhai KI; Stevens EM; Civantos AM; McCarty EB; Kumar A; Kohanski MA; Kennedy DW; Palmer JN; Bosso JV; Adappa ND
Am J Rhinol Allergy; 2021 Nov; 35(6):790-797. PubMed ID: 33691498
[TBL] [Abstract][Full Text] [Related]
15. SNOT-22 scores after 6 months of aspirin therapy are predictive of long-term quality of life in AERD.
Tripathi SH; Corr A; Kumar A; Ungerer H; Salmon M; Adappa ND; Bosso JV
Allergy Asthma Proc; 2023 Jan; 44(1):78-80. PubMed ID: 36719696
[No Abstract] [Full Text] [Related]
16. Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.
Ta V; White AA
J Allergy Clin Immunol Pract; 2015; 3(5):711-8. PubMed ID: 25858054
[TBL] [Abstract][Full Text] [Related]
17. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
18. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
19. A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
Esmaeilzadeh H; Zare M; Alyasin S; Nabavizadeh H; Mortazavi N; Kanannejad Z
Iran J Allergy Asthma Immunol; 2022 Oct; 21(5):512-523. PubMed ID: 36341560
[TBL] [Abstract][Full Text] [Related]
20. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
San Nicoló M; Högerle C; Gellrich D; Eder K; Pfrogner E; Gröger M
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):445-452. PubMed ID: 31655881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
